ID   EPM2A_HUMAN             Reviewed;         331 AA.
AC   O95278; B3KMU5; B4DRZ2; O95483; Q5T3F5; Q6IS15; Q8IU96; Q8IX24; Q8IX25;
AC   Q9BS66; Q9UEN2;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 2.
DT   03-AUG-2022, entry version 184.
DE   RecName: Full=Laforin {ECO:0000303|PubMed:11001928};
DE            EC=3.1.3.- {ECO:0000269|PubMed:16901901, ECO:0000269|PubMed:23922729, ECO:0000269|PubMed:25538239, ECO:0000269|PubMed:25544560, ECO:0000269|PubMed:26231210};
DE            EC=3.1.3.16 {ECO:0000305|PubMed:11001928};
DE            EC=3.1.3.48 {ECO:0000269|PubMed:11001928, ECO:0000269|PubMed:11220751};
DE   AltName: Full=Glucan phosphatase {ECO:0000303|PubMed:16901901, ECO:0000303|PubMed:25538239};
DE   AltName: Full=Glycogen phosphatase {ECO:0000303|PubMed:25538239, ECO:0000303|PubMed:25544560};
DE   AltName: Full=Lafora PTPase;
DE            Short=LAFPTPase {ECO:0000303|PubMed:11175283};
GN   Name=EPM2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), ALTERNATIVE SPLICING, TISSUE
RP   SPECIFICITY, VARIANTS EPM2 CYS-108; SER-279 AND LEU-293, AND VARIANT
RP   ASP-114.
RX   PubMed=9771710; DOI=10.1038/2470;
RA   Minassian B.A., Lee J.R., Herbrick J.-A., Huizenga J., Soder S.,
RA   Mungall A.J., Dunham I., Gardner R., Fong C.G., Carpenter S., Jardim L.,
RA   Satishchandra P., Andermann E., Snead O.C. III, Lopes-Cendes I.,
RA   Tsui L.-C., Delgado-Escueta A.V., Rouleau G.A., Scherer S.W.;
RT   "Mutations in a gene encoding a novel protein tyrosine phosphatase cause
RT   progressive myoclonus epilepsy.";
RL   Nat. Genet. 20:171-174(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTIONAL CHARACTERIZATION,
RP   CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS
RP   EPM2 HIS-171 AND LEU-293.
RC   TISSUE=Fetal brain;
RX   PubMed=11001928; DOI=10.1093/oxfordjournals.hmg.a018916;
RA   Ganesh S., Agarwala K.L., Ueda K., Akagi T., Shoda K., Usui T.,
RA   Hashikawa T., Osada H., Delgado-Escueta A.V., Yamakawa K.;
RT   "Laforin, defective in the progressive myoclonus epilepsy of Lafora type,
RT   is a dual-specificity phosphatase associated with polyribosomes.";
RL   Hum. Mol. Genet. 9:2251-2261(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Lee J.R., Scherer S.W.;
RL   Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 8), AND NUCLEOTIDE SEQUENCE [MRNA] OF
RP   25-331 (ISOFORM 4).
RC   TISSUE=Cerebellum, and Fetal brain;
RA   Ganesh S., Yamakawa K.;
RT   "Cloning of differentially spliced transcripts of the EPM2A gene.";
RL   Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 7 AND 8).
RC   TISSUE=Fetal brain, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 6).
RC   TISSUE=Hypothalamus, and Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 82-331 (ISOFORMS 1 AND 2), AND VARIANTS EPM2
RP   HIS-171; ILE-194; SER-279 AND ASN-294.
RX   PubMed=9931343; DOI=10.1093/hmg/8.2.345;
RA   Serratosa J.M., Gomez-Garre P., Gallardo M.E., Anta B., de Bernabe D.B.,
RA   Lindhout D., Augustijn P.B., Tassinari C.A., Malafosse R.M., Topcu M.,
RA   Grid D., Dravet C., Berkovic S.F., de Cordoba S.R.;
RT   "A novel protein tyrosine phosphatase gene is mutated in progressive
RT   myoclonus epilepsy of the Lafora type (EPM2).";
RL   Hum. Mol. Genet. 8:345-352(1999).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, MUTAGENESIS OF CYS-266,
RP   AND ACTIVE SITE.
RX   PubMed=11220751;
RX   DOI=10.1002/1531-8249(20010201)49:2<271::aid-ana52>3.0.co;2-d;
RA   Minassian B.A., Andrade D.M., Ianzano L., Young E.J., Chan E.,
RA   Ackerley C.A., Scherer S.W.;
RT   "Laforin is a cell membrane and endoplasmic reticulum-associated protein
RT   tyrosine phosphatase.";
RL   Ann. Neurol. 49:271-275(2001).
RN   [11]
RP   ALTERNATIVE SPLICING, AND SUBCELLULAR LOCATION (ISOFORM 2).
RX   PubMed=11883934; DOI=10.1006/bbrc.2002.6590;
RA   Ganesh S., Suzuki T., Yamakawa K.;
RT   "Alternative splicing modulates subcellular localization of laforin.";
RL   Biochem. Biophys. Res. Commun. 291:1134-1137(2002).
RN   [12]
RP   GLYCOGEN-BINDING, DOMAIN, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANT
RP   EPM2 GLY-32, CATALYTIC ACTIVITY, ACTIVE SITE, AND MUTAGENESIS OF LYS-87 AND
RP   CYS-266.
RX   PubMed=11739371; DOI=10.1074/jbc.c100686200;
RA   Wang J., Stuckey J.A., Wishart M.J., Dixon J.E.;
RT   "A unique carbohydrate binding domain targets the Lafora disease
RT   phosphatase to glycogen.";
RL   J. Biol. Chem. 277:2377-2380(2002).
RN   [13]
RP   INTERACTION WITH EPM2AIP1.
RX   PubMed=12782127; DOI=10.1016/s0888-7543(03)00094-6;
RA   Ianzano L., Zhao X.C., Minassian B.A., Scherer S.W.;
RT   "Identification of a novel protein interacting with laforin, the EPM2A
RT   progressive myoclonus epilepsy gene product.";
RL   Genomics 81:579-587(2003).
RN   [14]
RP   INTERACTION WITH HIRIP5.
RX   PubMed=12915448; DOI=10.1093/hmg/ddg253;
RA   Ganesh S., Tsurutani N., Suzuki T., Ueda K., Agarwala K.L., Osada H.,
RA   Delgado-Escueta A.V., Yamakawa K.;
RT   "The Lafora disease gene product laforin interacts with HIRIP5, a
RT   phylogenetically conserved protein containing a NifU-like domain.";
RL   Hum. Mol. Genet. 12:2359-2368(2003).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, SELF-INTERACTION, SUBCELLULAR LOCATION,
RP   GLYCOGEN-BINDING, INTERACTION WITH PPP1R3C, TISSUE SPECIFICITY, MUTAGENESIS
RP   OF ASP-235 AND CYS-266, ACTIVE SITE, AND CHARACTERIZATION OF VARIANTS EPM2
RP   GLY-32; LEU-84; CYS-108; ILE-194; SER-240; SER-279; LEU-293; ASN-294 AND
RP   LEU-301.
RX   PubMed=14532330; DOI=10.1093/hmg/ddg340;
RA   Fernandez-Sanchez M.E., Criado-Garcia O., Heath K.E., Garcia-Fojeda B.,
RA   Medrano-Fernandez I., Gomez-Garre P., Sanz P., Serratosa J.M.,
RA   Rodriguez de Cordoba S.;
RT   "Laforin, the dual-phosphatase responsible for Lafora disease, interacts
RT   with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances
RT   glycogen accumulation.";
RL   Hum. Mol. Genet. 12:3161-3171(2003).
RN   [16]
RP   BINDING TO GLYCOGEN AND LAFORA BODIES, DOMAIN, CHARACTERIZATION OF VARIANTS
RP   EPM2 PRO-25; LYS-28; GLY-32 AND LEU-88, AND CHARACTERIZATION OF VARIANT
RP   PRO-46.
RX   PubMed=14706656; DOI=10.1016/j.bbrc.2003.12.043;
RA   Ganesh S., Tsurutani N., Suzuki T., Hoshii Y., Ishihara T.,
RA   Delgado-Escueta A.V., Yamakawa K.;
RT   "The carbohydrate-binding domain of Lafora disease protein targets Lafora
RT   polyglucosan bodies.";
RL   Biochem. Biophys. Res. Commun. 313:1101-1109(2004).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND BINDING TO LAFORA GLUCAN BODIES.
RX   PubMed=15102711; DOI=10.1093/hmg/ddh130;
RA   Chan E.M., Ackerley C.A., Lohi H., Ianzano L., Cortez M.A., Shannon P.,
RA   Scherer S.W., Minassian B.A.;
RT   "Laforin preferentially binds the neurotoxic starch-like polyglucosans,
RT   which form in its absence in progressive myoclonus epilepsy.";
RL   Hum. Mol. Genet. 13:1117-1129(2004).
RN   [18]
RP   INTERACTION WITH NHLRC1, AND POLYUBIQUITINATION.
RX   PubMed=15930137; DOI=10.1073/pnas.0503285102;
RA   Gentry M.S., Worby C.A., Dixon J.E.;
RT   "Insights into Lafora disease: malin is an E3 ubiquitin ligase that
RT   ubiquitinates and promotes the degradation of laforin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:8501-8506(2005).
RN   [19]
RP   FUNCTION AS A GLUCAN PHOSPHATASE, CATALYTIC ACTIVITY, AND INTERACTION WITH
RP   PPP1R3B; PPP1R3C AND PPP1R3D.
RX   PubMed=16901901; DOI=10.1074/jbc.m606117200;
RA   Worby C.A., Gentry M.S., Dixon J.E.;
RT   "Laforin, a dual specificity phosphatase that dephosphorylates complex
RT   carbohydrates.";
RL   J. Biol. Chem. 281:30412-30418(2006).
RN   [20]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBUNIT.
RX   PubMed=16971387; DOI=10.1074/jbc.m607778200;
RA   Liu Y., Wang Y., Wu C., Liu Y., Zheng P.;
RT   "Dimerization of Laforin is required for its optimal phosphatase activity,
RT   regulation of GSK3beta phosphorylation, and Wnt signaling.";
RL   J. Biol. Chem. 281:34768-34774(2006).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17908927; DOI=10.1101/gad.1553207;
RA   Cheng A., Zhang M., Gentry M.S., Worby C.A., Dixon J.E., Saltiel A.R.;
RT   "A role for AGL ubiquitination in the glycogen storage disorders of Lafora
RT   and Cori's disease.";
RL   Genes Dev. 21:2399-2409(2007).
RN   [22]
RP   FUNCTION (ISOFORMS 1 AND 2), CATALYTIC ACTIVITY, HOMODIMERIZATION, SUBUNIT,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH NHLRC1 AND GLYCOGEN.
RX   PubMed=18617530; DOI=10.1093/hmg/ddn199;
RA   Dubey D., Ganesh S.;
RT   "Modulation of functional properties of laforin phosphatase by alternative
RT   splicing reveals a novel mechanism for the EPM2A gene in Lafora progressive
RT   myoclonus epilepsy.";
RL   Hum. Mol. Genet. 17:3010-3020(2008).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH PPP1R3C.
RX   PubMed=18070875; DOI=10.1074/jbc.m708712200;
RA   Worby C.A., Gentry M.S., Dixon J.E.;
RT   "Malin decreases glycogen accumulation by promoting the degradation of
RT   protein targeting to glycogen (PTG).";
RL   J. Biol. Chem. 283:4069-4076(2008).
RN   [24]
RP   FUNCTION, AND COMPLEX FORMATION WITH NHLRC1 AND HSP70.
RX   PubMed=19036738; DOI=10.1093/hmg/ddn398;
RA   Garyali P., Siwach P., Singh P.K., Puri R., Mittal S., Sengupta S.,
RA   Parihar R., Ganesh S.;
RT   "The malin-laforin complex suppresses the cellular toxicity of misfolded
RT   proteins by promoting their degradation through the ubiquitin-proteasome
RT   system.";
RL   Hum. Mol. Genet. 18:688-700(2009).
RN   [25]
RP   INTERACTION WITH MAPT.
RX   PubMed=19542233; DOI=10.1074/jbc.m109.009688;
RA   Puri R., Suzuki T., Yamakawa K., Ganesh S.;
RT   "Hyperphosphorylation and aggregation of Tau in laforin-deficient mice, an
RT   animal model for Lafora disease.";
RL   J. Biol. Chem. 284:22657-22663(2009).
RN   [26]
RP   FUNCTION.
RX   PubMed=20453062; DOI=10.1093/hmg/ddq190;
RA   Aguado C., Sarkar S., Korolchuk V.I., Criado O., Vernia S., Boya P.,
RA   Sanz P., de Cordoba S.R., Knecht E., Rubinsztein D.C.;
RT   "Laforin, the most common protein mutated in Lafora disease, regulates
RT   autophagy.";
RL   Hum. Mol. Genet. 19:2867-2876(2010).
RN   [27]
RP   PHOSPHORYLATION AT SER-25, MUTAGENESIS OF SER-25; SER-168; THR-187 AND
RP   THR-194, AND INTERACTION WITH NHLRC1; PPP1R3C AND PRKAA2.
RX   PubMed=21728993; DOI=10.1042/bj20110150;
RA   Roma-Mateo C., Solaz-Fuster Mdel C., Gimeno-Alcaniz J.V., Dukhande V.V.,
RA   Donderis J., Worby C.A., Marina A., Criado O., Koller A.,
RA   Rodriguez De Cordoba S., Gentry M.S., Sanz P.;
RT   "Laforin, a dual-specificity phosphatase involved in Lafora disease, is
RT   phosphorylated at Ser25 by AMP-activated protein kinase.";
RL   Biochem. J. 439:265-275(2011).
RN   [28]
RP   INTERACTION WITH PRDM8.
RX   PubMed=22961547; DOI=10.1093/brain/aws205;
RA   Turnbull J., Girard J.M., Lohi H., Chan E.M., Wang P., Tiberia E., Omer S.,
RA   Ahmed M., Bennett C., Chakrabarty A., Tyagi A., Liu Y., Pencea N., Zhao X.,
RA   Scherer S.W., Ackerley C.A., Minassian B.A.;
RT   "Early-onset Lafora body disease.";
RL   Brain 135:2684-2698(2012).
RN   [29]
RP   ALTERNATIVE SPLICING (ISOFORMS 4; 5; 6; 7 AND 9), FUNCTION (ISOFORMS 2 AND
RP   7), INTERACTION WITH NHLRC1 AND GLYCOGEN, SUBCELLULAR LOCATION, SUBUNIT,
RP   CATALYTIC ACTIVITY, MUTAGENESIS OF CYS-266, AND ACTIVE SITE.
RX   PubMed=22036712; DOI=10.1016/j.ygeno.2011.10.001;
RA   Dubey D., Parihar R., Ganesh S.;
RT   "Identification and characterization of novel splice variants of the human
RT   EPM2A gene mutated in Lafora progressive myoclonus epilepsy.";
RL   Genomics 99:36-43(2012).
RN   [30]
RP   FUNCTION, AND INTERACTION WITH PPP1R3D.
RX   PubMed=23624058; DOI=10.1016/j.biocel.2013.04.019;
RA   Rubio-Villena C., Garcia-Gimeno M.A., Sanz P.;
RT   "Glycogenic activity of R6, a protein phosphatase 1 regulatory subunit, is
RT   modulated by the laforin-malin complex.";
RL   Int. J. Biochem. Cell Biol. 45:1479-1488(2013).
RN   [31]
RP   CATALYTIC ACTIVITY, FUNCTION, INTERACTION WITH NHLRC1, SUBUNIT, AND
RP   MUTAGENESIS OF 109-CYS-CYS-110; CYS-123; CYS-169; CYS-205; CYS-250;
RP   CYS-266; CYS-329 AND 329-CYS--CYS-331.
RX   PubMed=23922729; DOI=10.1371/journal.pone.0069523;
RA   Sanchez-Martin P., Raththagala M., Bridges T.M., Husodo S., Gentry M.S.,
RA   Sanz P., Roma-Mateo C.;
RT   "Dimerization of the glucan phosphatase laforin requires the participation
RT   of cysteine 329.";
RL   PLoS ONE 8:E69523-E69523(2013).
RN   [32]
RP   CATALYTIC ACTIVITY, FUNCTION, MOTIF, AND CHARACTERIZATION OF VARIANT EPM2
RP   GLY-32.
RX   PubMed=26231210; DOI=10.1074/jbc.m115.658203;
RA   Meekins D.A., Raththagala M., Auger K.D., Turner B.D., Santelia D.,
RA   Koetting O., Gentry M.S., Vander Kooi C.W.;
RT   "Mechanistic insights into glucan phosphatase activity against polyglucan
RT   substrates.";
RL   J. Biol. Chem. 290:23361-23370(2015).
RN   [33] {ECO:0007744|PDB:4R30}
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 148-331, FUNCTION AS GLUCAN
RP   PHOSPHATASE, CATALYTIC ACTIVITY, SUBUNIT, AND MUTAGENESIS OF CYS-169;
RP   ARG-171; ASP-197; ASP-235; CYS-266; ARG-272 AND CYS-329.
RX   PubMed=25538239; DOI=10.1074/jbc.m114.627406;
RA   Sankhala R.S., Koksal A.C., Ho L., Nitschke F., Minassian B.A.,
RA   Cingolani G.;
RT   "Dimeric quaternary structure of human laforin.";
RL   J. Biol. Chem. 290:4552-4559(2015).
RN   [34] {ECO:0007744|PDB:4RKK}
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 1-329 IN COMPLEX WITH
RP   MALTOHEXAOSE AND PHOSPHATE, CATALYTIC ACTIVITY, FUNCTION, SUBUNIT,
RP   MUTAGENESIS OF VAL-8; LYS-87; TRP-99; ILE-126; THR-142; ASP-197; MET-236
RP   AND CYS-266, AND CHARACTERIZATION OF VARIANTS EPM2 GLY-32; HIS-171;
RP   SER-240; ASN-294 AND LEU-301.
RX   PubMed=25544560; DOI=10.1016/j.molcel.2014.11.020;
RA   Raththagala M., Brewer M.K., Parker M.W., Sherwood A.R., Wong B.K., Hsu S.,
RA   Bridges T.M., Paasch B.C., Hellman L.M., Husodo S., Meekins D.A.,
RA   Taylor A.O., Turner B.D., Auger K.D., Dukhande V.V., Chakravarthy S.,
RA   Sanz P., Woods V.L. Jr., Li S., Vander Kooi C.W., Gentry M.S.;
RT   "Structural mechanism of laforin function in glycogen dephosphorylation and
RT   lafora disease.";
RL   Mol. Cell 57:261-272(2015).
RN   [35]
RP   VARIANTS EPM2 LEU-84; SER-240 AND LEU-301.
RX   PubMed=11175283; DOI=10.1038/sj.ejhg.5200571;
RA   Gomez-Garre P., Sanz Y., Rodriguez de Cordoba S.R., Serratosa J.M.;
RT   "Mutational spectrum of the EPM2A gene in progressive myoclonus epilepsy of
RT   Lafora: high degree of allelic heterogeneity and prevalence of deletions.";
RL   Eur. J. Hum. Genet. 8:946-954(2000).
RN   [36]
RP   VARIANT PRO-46.
RX   PubMed=11735300; DOI=10.1006/mcpr.2001.0371;
RA   Ganesh S., Shoda K., Amano K., Uchiyama A., Kumada S., Moriyama N.,
RA   Hirose S., Yamakawa K.;
RT   "Mutation screening for Japanese Lafora's disease patients: identification
RT   of novel sequence variants in the coding and upstream regulatory regions of
RT   EPM2A gene.";
RL   Mol. Cell. Probes 15:281-289(2001).
RN   [37]
RP   VARIANTS EPM2 PRO-25; CYS-108; HIS-171 AND LEU-293, AND CHARACTERIZATION OF
RP   VARIANTS EPM2 GLY-32; CYS-108; ILE-194; SER-279 AND ASN-294.
RX   PubMed=12019207; DOI=10.1093/hmg/11.11.1263;
RA   Ganesh S., Delgado-Escueta A.V., Suzuki T., Francheschetti S., Riggio C.,
RA   Avanzini G., Rabinowicz A., Bohlega S., Bailey J., Alonso M.E.,
RA   Rasmussen A., Thomson A.E., Ochoa A., Prado A.J., Medina M.T., Yamakawa K.;
RT   "Genotype-phenotype correlations for EPM2A mutations in Lafora's
RT   progressive myoclonus epilepsy: exon 1 mutations associate with an early-
RT   onset cognitive deficit subphenotype.";
RL   Hum. Mol. Genet. 11:1263-1271(2002).
RN   [38]
RP   VARIANT EPM2 ALA-187.
RX   PubMed=12560877; DOI=10.1007/s100380300006;
RA   Ki C.S., Kong S.Y., Seo D.W., Hong S.B., Kim H.J., Kim J.W.;
RT   "Two novel mutations in the EPM2A gene in a Korean patient with Lafora's
RT   progressive myoclonus epilepsy.";
RL   J. Hum. Genet. 48:51-54(2003).
RN   [39]
RP   VARIANT EPM2 PRO-91.
RX   PubMed=15009235; DOI=10.1111/j.0013-9580.2004.33203.x;
RA   Annesi G., Sofia V., Gambardella A., Ciro Candiano I.C., Spadafora P.,
RA   Annesi F., Cutuli N., De Marco E.V., Civitelli D., Carrideo S.,
RA   Tarantino P., Barone R., Zappia M., Quattrone A.;
RT   "A novel exon 1 mutation in a patient with atypical Lafora progressive
RT   myoclonus epilepsy seen as childhood-onset cognitive deficit.";
RL   Epilepsia 45:294-295(2004).
RN   [40]
RP   VARIANTS EPM2 PRO-91; HIS-171 AND SER-279, CATALYTIC ACTIVITY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=14722920; DOI=10.1002/humu.10306;
RA   Ianzano L., Young E.J., Zhao X.C., Chan E.M., Rodriguez M.T., Torrado M.V.,
RA   Scherer S.W., Minassian B.A.;
RT   "Loss of function of the cytoplasmic isoform of the protein laforin (EPM2A)
RT   causes Lafora progressive myoclonus epilepsy.";
RL   Hum. Mutat. 23:170-176(2004).
RN   [41]
RP   VARIANT PRO-46.
RX   PubMed=16021330; DOI=10.1007/s10038-005-0263-7;
RA   Singh S., Suzuki T., Uchiyama A., Kumada S., Moriyama N., Hirose S.,
RA   Takahashi Y., Sugie H., Mizoguchi K., Inoue Y., Kimura K., Sawaishi Y.,
RA   Yamakawa K., Ganesh S.;
RT   "Mutations in the NHLRC1 gene are the common cause for Lafora disease in
RT   the Japanese population.";
RL   J. Hum. Genet. 50:347-352(2005).
RN   [42]
RP   VARIANTS EPM2 ASN-140; TYR-148; LYS-210 AND TRP-310, CHARACTERIZATION OF
RP   VARIANT EPM2 TRP-310, AND SUBCELLULAR LOCATION.
RX   PubMed=18311786; DOI=10.1002/humu.20737;
RA   Singh S., Satishchandra P., Shankar S.K., Ganesh S.;
RT   "Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations
RT   and their impact on subcellular localization of laforin and malin.";
RL   Hum. Mutat. 29:E1-12(2008).
CC   -!- FUNCTION: Plays an important role in preventing glycogen
CC       hyperphosphorylation and the formation of insoluble aggregates, via its
CC       activity as glycogen phosphatase, and by promoting the ubiquitination
CC       of proteins involved in glycogen metabolism via its interaction with
CC       the E3 ubiquitin ligase NHLRC1/malin. Shows strong phosphatase activity
CC       towards complex carbohydrates in vitro, avoiding glycogen
CC       hyperphosphorylation which is associated with reduced branching and
CC       formation of insoluble aggregates (PubMed:16901901, PubMed:23922729,
CC       PubMed:26231210, PubMed:25538239, PubMed:25544560). Dephosphorylates
CC       phosphotyrosine and synthetic substrates, such as para-
CC       nitrophenylphosphate (pNPP), and has low activity with phosphoserine
CC       and phosphothreonine substrates (in vitro) (PubMed:11001928,
CC       PubMed:11220751, PubMed:11739371, PubMed:14532330, PubMed:16971387,
CC       PubMed:18617530, PubMed:22036712, PubMed:23922729, PubMed:14722920).
CC       Has been shown to dephosphorylate MAPT (By similarity). Forms a complex
CC       with NHLRC1/malin and HSP70, which suppresses the cellular toxicity of
CC       misfolded proteins by promoting their degradation through the
CC       ubiquitin-proteasome system (UPS). Acts as a scaffold protein to
CC       facilitate PPP1R3C/PTG ubiquitination by NHLRC1/malin
CC       (PubMed:23922729). Also promotes proteasome-independent protein
CC       degradation through the macroautophagy pathway (PubMed:20453062).
CC       {ECO:0000250|UniProtKB:Q9WUA5, ECO:0000269|PubMed:11001928,
CC       ECO:0000269|PubMed:11220751, ECO:0000269|PubMed:11739371,
CC       ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:14722920,
CC       ECO:0000269|PubMed:16901901, ECO:0000269|PubMed:16971387,
CC       ECO:0000269|PubMed:18070875, ECO:0000269|PubMed:18617530,
CC       ECO:0000269|PubMed:19036738, ECO:0000269|PubMed:20453062,
CC       ECO:0000269|PubMed:22036712, ECO:0000269|PubMed:23624058,
CC       ECO:0000269|PubMed:23922729, ECO:0000269|PubMed:25538239,
CC       ECO:0000269|PubMed:25544560, ECO:0000269|PubMed:26231210}.
CC   -!- FUNCTION: [Isoform 2]: Does not bind to glycogen (PubMed:18617530).
CC       Lacks phosphatase activity and might function as a dominant-negative
CC       regulator for the phosphatase activity of isoform 1 and isoform 7
CC       (PubMed:18617530, PubMed:22036712). {ECO:0000269|PubMed:18617530,
CC       ECO:0000269|PubMed:22036712}.
CC   -!- FUNCTION: [Isoform 7]: Has phosphatase activity (in vitro).
CC       {ECO:0000269|PubMed:22036712}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-tyrosyl-[protein] = L-tyrosyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:10684, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15377, ChEBI:CHEBI:43474, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620; EC=3.1.3.48; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU10044, ECO:0000269|PubMed:11001928,
CC         ECO:0000269|PubMed:11220751};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-seryl-[protein] = L-seryl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:20629, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15377, ChEBI:CHEBI:29999, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:83421; EC=3.1.3.16;
CC         Evidence={ECO:0000305|PubMed:11001928};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + O-phospho-L-threonyl-[protein] = L-threonyl-[protein] +
CC         phosphate; Xref=Rhea:RHEA:47004, Rhea:RHEA-COMP:11060, Rhea:RHEA-
CC         COMP:11605, ChEBI:CHEBI:15377, ChEBI:CHEBI:30013, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:61977; EC=3.1.3.16;
CC         Evidence={ECO:0000305|PubMed:11001928};
CC   -!- SUBUNIT: Homodimer (PubMed:16971387, PubMed:18617530, PubMed:23922729,
CC       PubMed:25538239, PubMed:25544560). Interacts with itself
CC       (PubMed:14532330). Interacts with PPP1R3B, PPP1R3C, PPP1R3D, HIRIP5,
CC       and EPM2AIP1 (PubMed:12782127, PubMed:12915448, PubMed:14532330,
CC       PubMed:16901901, PubMed:18070875). Binds glycogen and Lafora bodies
CC       (PubMed:11739371, PubMed:14532330, PubMed:14706656, PubMed:15102711,
CC       PubMed:18617530, PubMed:22036712). Interacts with NHLRC1/malin (via the
CC       NHL repeats) (PubMed:15930137, PubMed:22036712, PubMed:23922729). Forms
CC       a complex with NHLRC1/malin and HSP70 (PubMed:19036738). Interacts with
CC       PPP1R3D; in the presence of NHLC1/malin the interaction leads to
CC       ubiquitination and autophagic degradation of PPP1R3D. Interacts (via
CC       the phosphatase domain) with MAPT/Tau; the interaction dephosphorylates
CC       MAPT (PubMed:19542233). Isoform 1 and isoform 2 interact to form a
CC       heterodimeric complex that lacks phosphatase activity (in vitro)
CC       (PubMed:18617530). Active phosphatase isoform 7 and isoform 1 interact
CC       with each other, but give rise to lower phosphatase activity than
CC       isoform 1 or isoform 7 by themselves (in vitro) (PubMed:22036712).
CC       Active phosphatase isoform 7 and inactive isoform 2 interact with each
CC       other, but give rise to lower phosphatase activity than isoform 7 by
CC       itself (in vitro) (PubMed:22036712). Interacts with PRDM8
CC       (PubMed:22961547). {ECO:0000269|PubMed:11739371,
CC       ECO:0000269|PubMed:12782127, ECO:0000269|PubMed:12915448,
CC       ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:14706656,
CC       ECO:0000269|PubMed:15102711, ECO:0000269|PubMed:15930137,
CC       ECO:0000269|PubMed:16901901, ECO:0000269|PubMed:16971387,
CC       ECO:0000269|PubMed:18070875, ECO:0000269|PubMed:18617530,
CC       ECO:0000269|PubMed:19542233, ECO:0000269|PubMed:22036712,
CC       ECO:0000269|PubMed:22961547, ECO:0000269|PubMed:23624058,
CC       ECO:0000269|PubMed:23922729, ECO:0000269|PubMed:25538239,
CC       ECO:0000269|PubMed:25544560}.
CC   -!- INTERACTION:
CC       O95278; Q6VVB1: NHLRC1; NbExp=7; IntAct=EBI-2506661, EBI-6426628;
CC       O95278; Q9UQK1: PPP1R3C; NbExp=5; IntAct=EBI-2506661, EBI-2506727;
CC       O95278-6; P06307: CCK; NbExp=3; IntAct=EBI-25836908, EBI-6624398;
CC       O95278-6; P13473-2: LAMP2; NbExp=3; IntAct=EBI-25836908, EBI-21591415;
CC       O95278-6; Q9Y371: SH3GLB1; NbExp=3; IntAct=EBI-25836908, EBI-2623095;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11001928,
CC       ECO:0000269|PubMed:11220751, ECO:0000269|PubMed:11739371,
CC       ECO:0000269|PubMed:15102711, ECO:0000269|PubMed:17908927}. Note=Under
CC       glycogenolytic conditions localizes to the nucleus.
CC       {ECO:0000269|PubMed:17908927}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm
CC       {ECO:0000269|PubMed:11001928, ECO:0000269|PubMed:11739371,
CC       ECO:0000269|PubMed:11883934, ECO:0000269|PubMed:14532330,
CC       ECO:0000269|PubMed:18311786, ECO:0000269|PubMed:18617530,
CC       ECO:0000269|PubMed:22036712}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:11001928, ECO:0000269|PubMed:14722920,
CC       ECO:0000269|PubMed:18311786}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:11001928, ECO:0000269|PubMed:18311786}; Cytoplasmic
CC       side {ECO:0000269|PubMed:11001928, ECO:0000269|PubMed:18311786}. Cell
CC       membrane {ECO:0000269|PubMed:11220751}. Note=Colocalizes with glycogen
CC       synthase in punctate structures in the cytoplasm (PubMed:11739371,
CC       PubMed:14532330). Primarily associated with polyribosomes at the rough
CC       endoplasmic reticulum, and also detected at the plasma membrane
CC       (PubMed:11001928, PubMed:11220751, PubMed:11883934, PubMed:18311786).
CC       {ECO:0000269|PubMed:11001928, ECO:0000269|PubMed:11220751,
CC       ECO:0000269|PubMed:11739371, ECO:0000269|PubMed:11883934,
CC       ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:18311786}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm
CC       {ECO:0000269|PubMed:18617530}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:11883934}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:11883934}; Cytoplasmic side
CC       {ECO:0000269|PubMed:11883934}. Cell membrane
CC       {ECO:0000269|PubMed:11883934}. Nucleus {ECO:0000269|PubMed:11883934,
CC       ECO:0000269|PubMed:14722920, ECO:0000269|PubMed:18617530}. Note=Also
CC       found in the nucleus. {ECO:0000269|PubMed:11883934,
CC       ECO:0000269|PubMed:18617530}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Cytoplasm
CC       {ECO:0000269|PubMed:22036712}. Nucleus {ECO:0000269|PubMed:22036712}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 5]: Cytoplasm
CC       {ECO:0000269|PubMed:22036712}. Nucleus {ECO:0000269|PubMed:22036712}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 7]: Cytoplasm
CC       {ECO:0000269|PubMed:22036712}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=8;
CC       Name=1; Synonyms=A, LDH1 {ECO:0000303|PubMed:11883934}, Laf331
CC       {ECO:0000303|PubMed:22036712};
CC         IsoId=O95278-1; Sequence=Displayed;
CC       Name=2; Synonyms=B, C-terISO, Laf317 {ECO:0000303|PubMed:22036712};
CC         IsoId=O95278-2; Sequence=VSP_011017, VSP_011018;
CC       Name=4; Synonyms=Laf152 {ECO:0000303|PubMed:22036712};
CC         IsoId=O95278-4; Sequence=VSP_011015, VSP_011016;
CC       Name=5; Synonyms=Laf224 {ECO:0000303|PubMed:22036712};
CC         IsoId=O95278-5; Sequence=VSP_042496, VSP_042497;
CC       Name=6; Synonyms=Laf88 {ECO:0000303|PubMed:22036712};
CC         IsoId=O95278-6; Sequence=VSP_042494;
CC       Name=7; Synonyms=Laf177 {ECO:0000303|PubMed:22036712};
CC         IsoId=O95278-7; Sequence=VSP_042495;
CC       Name=8;
CC         IsoId=O95278-8; Sequence=VSP_042493;
CC       Name=9; Synonyms=POCR {ECO:0000303|PubMed:22036712};
CC         IsoId=B3EWF7-1; Sequence=External;
CC   -!- TISSUE SPECIFICITY: Expressed in heart, skeletal muscle, kidney,
CC       pancreas and brain. Isoform 4 is also expressed in the placenta.
CC       {ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:9771710}.
CC   -!- DOMAIN: The CBM20 domain mediates binding to cytoplasmic glycogen and
CC       to Lafora polyglucosan bodies. {ECO:0000269|PubMed:11739371,
CC       ECO:0000269|PubMed:14706656}.
CC   -!- PTM: Polyubiquitinated by NHLRC1/malin. {ECO:0000269|PubMed:15930137}.
CC   -!- PTM: Phosphorylation on Ser-25 by AMPK affects the phosphatase activity
CC       of the enzyme and its ability to homodimerize and interact with NHLRC1,
CC       PPP1R3C or PRKAA2. {ECO:0000269|PubMed:21728993}.
CC   -!- DISEASE: Epilepsy, progressive myoclonic 2 (EPM2) [MIM:254780]: A form
CC       of progressive myoclonic epilepsy, a clinically and genetically
CC       heterogeneous group of disorders defined by the combination of action
CC       and reflex myoclonus, other types of epileptic seizures, and
CC       progressive neurodegeneration and neurocognitive impairment. EPM2 is an
CC       autosomal recessive and severe form of adolescent-onset progressive
CC       epilepsy. Typically, as seizures increase in frequency, cognitive
CC       function declines towards dementia, and affected individuals die
CC       usually within 10 years after onset. EPM2 occurs worldwide, but it is
CC       particularly common in the mediterranean countries of southern Europe
CC       and northern Africa, in southern India and in the Middle East. At the
CC       cellular level, it is characterized by accumulation of starch-like
CC       polyglucosans called Lafora bodies (LBs) that are most abundant in
CC       organs with the highest glucose metabolism: brain, heart, liver and
CC       skeletal muscle. Among other conditions involving polyglucosans, EPM2
CC       is unique in that the inclusions are in neuronal dendrites but not
CC       axons and the forming polyglucosan fibrils are associated with the
CC       endoplasmic reticulum. {ECO:0000269|PubMed:11001928,
CC       ECO:0000269|PubMed:11175283, ECO:0000269|PubMed:11739371,
CC       ECO:0000269|PubMed:12019207, ECO:0000269|PubMed:12560877,
CC       ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:14706656,
CC       ECO:0000269|PubMed:14722920, ECO:0000269|PubMed:15009235,
CC       ECO:0000269|PubMed:18311786, ECO:0000269|PubMed:25544560,
CC       ECO:0000269|PubMed:26231210, ECO:0000269|PubMed:9771710,
CC       ECO:0000269|PubMed:9931343}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative splicing. May be
CC       due to an intron retention. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 6]: Produced by alternative initiation at Met-
CC       244 of isoform 1. Transcript amplified but protein not detected.
CC       {ECO:0000269|PubMed:22036712}.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative splicing. Active
CC       phosphatase. {ECO:0000269|PubMed:22036712}.
CC   -!- MISCELLANEOUS: [Isoform 8]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein-tyrosine phosphatase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAO15523.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact.; Evidence={ECO:0000305};
CC       Sequence=BAG51107.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=The Lafora progressive myoclonus epilepsy mutation
CC       and polymorphism database;
CC       URL="http://projects.tcag.ca/lafora/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF084535; AAC83347.2; -; mRNA.
DR   EMBL; AF284580; AAG18377.1; -; mRNA.
DR   EMBL; AF454491; AAO15523.1; ALT_SEQ; mRNA.
DR   EMBL; AF454492; AAO15524.1; -; mRNA.
DR   EMBL; AF454493; AAO15525.1; -; mRNA.
DR   EMBL; AF454494; AAO15526.1; -; mRNA.
DR   EMBL; AK022721; BAG51107.1; ALT_FRAME; mRNA.
DR   EMBL; AK299497; BAG61454.1; -; mRNA.
DR   EMBL; AL023806; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL365193; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW47844.1; -; Genomic_DNA.
DR   EMBL; BC005286; AAH05286.1; -; mRNA.
DR   EMBL; BC070047; AAH70047.1; -; mRNA.
DR   EMBL; AJ130763; CAA10199.1; -; mRNA.
DR   EMBL; AJ130764; CAA10200.1; -; mRNA.
DR   CCDS; CCDS5206.1; -. [O95278-1]
DR   CCDS; CCDS87452.1; -. [O95278-8]
DR   CCDS; CCDS87453.1; -. [O95278-5]
DR   CCDS; CCDS87454.1; -. [O95278-2]
DR   RefSeq; NP_001018051.1; NM_001018041.1. [O95278-2]
DR   RefSeq; NP_005661.1; NM_005670.3. [O95278-1]
DR   RefSeq; XP_006715627.1; XM_006715564.3.
DR   RefSeq; XP_011534418.1; XM_011536116.1. [O95278-8]
DR   RefSeq; XP_016866789.1; XM_017011300.1.
DR   RefSeq; XP_016866790.1; XM_017011301.1. [O95278-7]
DR   RefSeq; XP_016866791.1; XM_017011302.1. [O95278-7]
DR   PDB; 4R30; X-ray; 2.30 A; A/B/C/D=148-331.
DR   PDB; 4RKK; X-ray; 2.40 A; A/C=1-329.
DR   PDBsum; 4R30; -.
DR   PDBsum; 4RKK; -.
DR   AlphaFoldDB; O95278; -.
DR   SMR; O95278; -.
DR   BioGRID; 113679; 51.
DR   IntAct; O95278; 9.
DR   STRING; 9606.ENSP00000356489; -.
DR   BindingDB; O95278; -.
DR   ChEMBL; CHEMBL2311242; -.
DR   CAZy; CBM20; Carbohydrate-Binding Module Family 20.
DR   DEPOD; EPM2A; -.
DR   iPTMnet; O95278; -.
DR   PhosphoSitePlus; O95278; -.
DR   BioMuta; EPM2A; -.
DR   EPD; O95278; -.
DR   MassIVE; O95278; -.
DR   PaxDb; O95278; -.
DR   PeptideAtlas; O95278; -.
DR   PRIDE; O95278; -.
DR   ProteomicsDB; 50779; -. [O95278-1]
DR   ProteomicsDB; 50780; -. [O95278-2]
DR   ProteomicsDB; 50782; -. [O95278-4]
DR   ProteomicsDB; 50783; -. [O95278-5]
DR   ProteomicsDB; 50784; -. [O95278-6]
DR   ProteomicsDB; 50785; -. [O95278-7]
DR   ProteomicsDB; 50786; -. [O95278-8]
DR   ABCD; O95278; 1 sequenced antibody.
DR   Antibodypedia; 19839; 527 antibodies from 38 providers.
DR   DNASU; 7957; -.
DR   Ensembl; ENST00000367519.9; ENSP00000356489.3; ENSG00000112425.16. [O95278-1]
DR   Ensembl; ENST00000435470.2; ENSP00000405913.2; ENSG00000112425.16. [O95278-2]
DR   Ensembl; ENST00000611340.5; ENSP00000480268.1; ENSG00000112425.16. [O95278-8]
DR   Ensembl; ENST00000638262.1; ENSP00000492876.1; ENSG00000112425.16. [O95278-5]
DR   Ensembl; ENST00000638778.1; ENSP00000491353.1; ENSG00000112425.16. [O95278-8]
DR   Ensembl; ENST00000638783.1; ENSP00000491338.1; ENSG00000112425.16. [O95278-8]
DR   Ensembl; ENST00000639423.1; ENSP00000492701.1; ENSG00000112425.16. [O95278-8]
DR   Ensembl; ENST00000639465.1; ENSP00000491180.1; ENSG00000112425.16. [O95278-8]
DR   GeneID; 7957; -.
DR   KEGG; hsa:7957; -.
DR   MANE-Select; ENST00000367519.9; ENSP00000356489.3; NM_005670.4; NP_005661.1.
DR   UCSC; uc003qkw.4; human. [O95278-1]
DR   CTD; 7957; -.
DR   DisGeNET; 7957; -.
DR   GeneCards; EPM2A; -.
DR   GeneReviews; EPM2A; -.
DR   HGNC; HGNC:3413; EPM2A.
DR   HPA; ENSG00000112425; Tissue enhanced (skeletal muscle, tongue).
DR   MalaCards; EPM2A; -.
DR   MIM; 254780; phenotype.
DR   MIM; 607566; gene.
DR   neXtProt; NX_O95278; -.
DR   OpenTargets; ENSG00000112425; -.
DR   Orphanet; 501; Lafora disease.
DR   PharmGKB; PA27832; -.
DR   VEuPathDB; HostDB:ENSG00000112425; -.
DR   eggNOG; KOG1716; Eukaryota.
DR   GeneTree; ENSGT00390000010101; -.
DR   HOGENOM; CLU_076792_0_0_1; -.
DR   OMA; HLYKDCG; -.
DR   OrthoDB; 865142at2759; -.
DR   PhylomeDB; O95278; -.
DR   TreeFam; TF332841; -.
DR   BRENDA; 3.1.3.16; 2681.
DR   PathwayCommons; O95278; -.
DR   Reactome; R-HSA-3322077; Glycogen synthesis.
DR   Reactome; R-HSA-3785653; Myoclonic epilepsy of Lafora.
DR   SignaLink; O95278; -.
DR   SIGNOR; O95278; -.
DR   BioGRID-ORCS; 7957; 9 hits in 1076 CRISPR screens.
DR   ChiTaRS; EPM2A; human.
DR   GenomeRNAi; 7957; -.
DR   Pharos; O95278; Tbio.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000112425; Expressed in skeletal muscle tissue of rectus abdominis and 203 other tissues.
DR   ExpressionAtlas; O95278; baseline and differential.
DR   Genevisible; O95278; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0098556; C:cytoplasmic side of rough endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0030246; F:carbohydrate binding; IDA:UniProtKB.
DR   GO; GO:0019203; F:carbohydrate phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004373; F:glycogen (starch) synthase activity; IEA:Ensembl.
DR   GO; GO:2001069; F:glycogen binding; IDA:UniProtKB.
DR   GO; GO:0017018; F:myosin phosphatase activity; IEA:UniProtKB-EC.
DR   GO; GO:0016791; F:phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0046983; F:protein dimerization activity; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0004725; F:protein tyrosine phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0008138; F:protein tyrosine/serine/threonine phosphatase activity; IEA:InterPro.
DR   GO; GO:2001070; F:starch binding; IEA:Ensembl.
DR   GO; GO:0000045; P:autophagosome assembly; IEA:Ensembl.
DR   GO; GO:0006816; P:calcium ion transport; IEA:Ensembl.
DR   GO; GO:0046835; P:carbohydrate phosphorylation; IEA:Ensembl.
DR   GO; GO:0016311; P:dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl.
DR   GO; GO:0005978; P:glycogen biosynthetic process; TAS:Reactome.
DR   GO; GO:0005977; P:glycogen metabolic process; IMP:UniProtKB.
DR   GO; GO:0046959; P:habituation; IEA:Ensembl.
DR   GO; GO:0015813; P:L-glutamate transmembrane transport; IEA:Ensembl.
DR   GO; GO:0007005; P:mitochondrion organization; IEA:Ensembl.
DR   GO; GO:0045786; P:negative regulation of cell cycle; IEA:Ensembl.
DR   GO; GO:0035305; P:negative regulation of dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0033137; P:negative regulation of peptidyl-serine phosphorylation; IEA:Ensembl.
DR   GO; GO:0010923; P:negative regulation of phosphatase activity; IDA:UniProtKB.
DR   GO; GO:0035335; P:peptidyl-tyrosine dephosphorylation; IMP:UniProtKB.
DR   GO; GO:0046838; P:phosphorylated carbohydrate dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; IEA:Ensembl.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0006470; P:protein dephosphorylation; IDA:UniProtKB.
DR   GO; GO:0001558; P:regulation of cell growth; IEA:Ensembl.
DR   GO; GO:2000465; P:regulation of glycogen (starch) synthase activity; IEA:Ensembl.
DR   GO; GO:0061136; P:regulation of proteasomal protein catabolic process; IEA:Ensembl.
DR   GO; GO:0042306; P:regulation of protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0045859; P:regulation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:1903076; P:regulation of protein localization to plasma membrane; IEA:Ensembl.
DR   GO; GO:0031396; P:regulation of protein ubiquitination; IEA:Ensembl.
DR   GO; GO:1904666; P:regulation of ubiquitin protein ligase activity; IEA:Ensembl.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:Ensembl.
DR   CDD; cd05806; CBM20_laforin; 1.
DR   CDD; cd14526; DSP_laforin-like; 1.
DR   DisProt; DP02647; -.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.90.190.10; -; 1.
DR   InterPro; IPR013784; Carb-bd-like_fold.
DR   InterPro; IPR034831; CBM20_laforin.
DR   InterPro; IPR002044; CBM_fam20.
DR   InterPro; IPR045204; DSP_laforin-like.
DR   InterPro; IPR000340; Dual-sp_phosphatase_cat-dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR042942; Laforin.
DR   InterPro; IPR029021; Prot-tyrosine_phosphatase-like.
DR   InterPro; IPR016130; Tyr_Pase_AS.
DR   InterPro; IPR000387; Tyr_Pase_dom.
DR   InterPro; IPR020422; TYR_PHOSPHATASE_DUAL_dom.
DR   PANTHER; PTHR46864; PTHR46864; 1.
DR   Pfam; PF00686; CBM_20; 1.
DR   Pfam; PF00782; DSPc; 1.
DR   SMART; SM01065; CBM_2; 1.
DR   SMART; SM00195; DSPc; 1.
DR   SUPFAM; SSF49452; SSF49452; 1.
DR   SUPFAM; SSF52799; SSF52799; 1.
DR   PROSITE; PS51166; CBM20; 1.
DR   PROSITE; PS00383; TYR_PHOSPHATASE_1; 1.
DR   PROSITE; PS50056; TYR_PHOSPHATASE_2; 1.
DR   PROSITE; PS50054; TYR_PHOSPHATASE_DUAL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing; Autophagy;
KW   Carbohydrate metabolism; Cell membrane; Cytoplasm; Disease variant;
KW   Endoplasmic reticulum; Epilepsy; Glycogen metabolism;
KW   Glycogen storage disease; Hydrolase; Membrane; Neurodegeneration; Nucleus;
KW   Phosphoprotein; Protein phosphatase; Reference proteome; Ubl conjugation.
FT   CHAIN           1..331
FT                   /note="Laforin"
FT                   /id="PRO_0000094838"
FT   DOMAIN          1..124
FT                   /note="CBM20"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00594"
FT   DOMAIN          156..323
FT                   /note="Tyrosine-protein phosphatase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00160"
FT   MOTIF           266..272
FT                   /note="Glucan phosphatase signature motif CXAGXGR"
FT                   /evidence="ECO:0000305|PubMed:25544560,
FT                   ECO:0000305|PubMed:26231210"
FT   ACT_SITE        266
FT                   /note="Phosphocysteine intermediate"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00160,
FT                   ECO:0000305|PubMed:11220751, ECO:0000305|PubMed:11739371,
FT                   ECO:0000305|PubMed:14532330, ECO:0000305|PubMed:22036712,
FT                   ECO:0000305|PubMed:25538239, ECO:0000305|PubMed:25544560"
FT   BINDING         32
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:25544560,
FT                   ECO:0007744|PDB:4RKK"
FT   BINDING         87
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:25544560,
FT                   ECO:0007744|PDB:4RKK"
FT   BINDING         103..107
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:25544560,
FT                   ECO:0007744|PDB:4RKK"
FT   BINDING         197
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:25544560,
FT                   ECO:0007744|PDB:4RKK"
FT   BINDING         235
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:25544560,
FT                   ECO:0007744|PDB:4RKK"
FT   BINDING         241
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:25544560,
FT                   ECO:0007744|PDB:4RKK"
FT   BINDING         267..272
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:25544560,
FT                   ECO:0007744|PDB:4RKK"
FT   BINDING         304
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000269|PubMed:25544560,
FT                   ECO:0007744|PDB:4RKK"
FT   SITE            329
FT                   /note="Required for homodimerization"
FT                   /evidence="ECO:0000269|PubMed:23922729"
FT   MOD_RES         25
FT                   /note="Phosphoserine; by AMPK"
FT                   /evidence="ECO:0000269|PubMed:21728993"
FT   VAR_SEQ         1..243
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_042494"
FT   VAR_SEQ         1..159
FT                   /note="MRFRFGVVVPPAVAGARPELLVVGSRPELGRWEPRGAVRLRPAGTAAGDGAL
FT                   ALQEPGLWLGEVELAAEEAAQDGAEPGRVDTFWYKFLKREPGGELSWEGNGPHHDRCCT
FT                   YNENNLVDGVYCLPIGHWIEATGHTNEMKHTTDFYFNIAGHQAMHYSR -> MIFNK
FT                   (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_042495"
FT   VAR_SEQ         1..138
FT                   /note="Missing (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.4"
FT                   /id="VSP_042493"
FT   VAR_SEQ         102..199
FT                   /note="NGPHHDRCCTYNENNLVDGVYCLPIGHWIEATGHTNEMKHTTDFYFNIAGHQ
FT                   AMHYSRILPNIWLGSCPRQVEHVTIKLKHELGITAVMNFQTEWDIV -> IASRRLPPA
FT                   QSGSSGPHPQPGPRPRAGPAGPGGARPGLFARVPAHSPGDLG (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_011015"
FT   VAR_SEQ         160..293
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_042496"
FT   VAR_SEQ         200..331
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_011016"
FT   VAR_SEQ         294..331
FT                   /note="YFLMAKRPAVYIDEEALARAQEDFFQKFGKVRSSVCSL -> PSTDAAPGGV
FT                   PAACAAGEGTHRVRALQRWGGPLHRGCLRLAPVCDGLESEEGAVFPHGQEAGCLH (in
FT                   isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_042497"
FT   VAR_SEQ         310..320
FT                   /note="LARAQEDFFQK -> ASQDTFPL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9771710,
FT                   ECO:0000303|PubMed:9931343"
FT                   /id="VSP_011017"
FT   VAR_SEQ         321..331
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9771710,
FT                   ECO:0000303|PubMed:9931343"
FT                   /id="VSP_011018"
FT   VARIANT         25
FT                   /note="S -> P (in EPM2; atypical form; does not affect
FT                   glycogen binding)"
FT                   /evidence="ECO:0000269|PubMed:12019207,
FT                   ECO:0000269|PubMed:14706656"
FT                   /id="VAR_019465"
FT   VARIANT         28
FT                   /note="E -> K (in EPM2; does not affect glycogen binding)"
FT                   /evidence="ECO:0000269|PubMed:14706656"
FT                   /id="VAR_019466"
FT   VARIANT         32
FT                   /note="W -> G (in EPM2; impairs protein stability; affects
FT                   phosphatase activity; abolishes glycogen binding; abolishes
FT                   phosphatase activity with insoluble glucan; disrupts the
FT                   interaction with PPP1R3C; dbSNP:rs104893955)"
FT                   /evidence="ECO:0000269|PubMed:11739371,
FT                   ECO:0000269|PubMed:12019207, ECO:0000269|PubMed:14532330,
FT                   ECO:0000269|PubMed:14706656, ECO:0000269|PubMed:25544560,
FT                   ECO:0000269|PubMed:26231210"
FT                   /id="VAR_019467"
FT   VARIANT         46
FT                   /note="A -> P (does not affect glycogen binding;
FT                   dbSNP:rs374338349)"
FT                   /evidence="ECO:0000269|PubMed:11735300,
FT                   ECO:0000269|PubMed:14706656, ECO:0000269|PubMed:16021330"
FT                   /id="VAR_019468"
FT   VARIANT         84
FT                   /note="F -> L (in EPM2; affects phosphatase activity and
FT                   glycogen binding; disrupts the interaction with PPP1R3C;
FT                   dbSNP:rs1362231306)"
FT                   /evidence="ECO:0000269|PubMed:11175283,
FT                   ECO:0000269|PubMed:14532330"
FT                   /id="VAR_019469"
FT   VARIANT         88
FT                   /note="F -> L (in EPM2; does not affect glycogen binding;
FT                   dbSNP:rs1034706422 and dbSNP:rs1463000703)"
FT                   /evidence="ECO:0000269|PubMed:14706656"
FT                   /id="VAR_019470"
FT   VARIANT         91
FT                   /note="R -> P (in EPM2; atypical form; learning difficuties
FT                   with childhood-onset)"
FT                   /evidence="ECO:0000269|PubMed:14722920,
FT                   ECO:0000269|PubMed:15009235"
FT                   /id="VAR_019471"
FT   VARIANT         108
FT                   /note="R -> C (in EPM2; loss of phosphatase activity;
FT                   reduced self-interaction capacity; disrupts the interaction
FT                   with PPP1R3C; dbSNP:rs137852915)"
FT                   /evidence="ECO:0000269|PubMed:12019207,
FT                   ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:9771710"
FT                   /id="VAR_019472"
FT   VARIANT         114
FT                   /note="E -> D"
FT                   /evidence="ECO:0000269|PubMed:9771710"
FT                   /id="VAR_019473"
FT   VARIANT         140
FT                   /note="K -> N (in EPM2)"
FT                   /evidence="ECO:0000269|PubMed:18311786"
FT                   /id="VAR_046383"
FT   VARIANT         148
FT                   /note="N -> Y (in EPM2)"
FT                   /evidence="ECO:0000269|PubMed:18311786"
FT                   /id="VAR_046384"
FT   VARIANT         171
FT                   /note="R -> H (in EPM2; results in ubiquitin-positive
FT                   perinuclear aggregates; no effect on glycogen binding;
FT                   abolishes phosphatase activity; may affect proper folding;
FT                   dbSNP:rs137852916)"
FT                   /evidence="ECO:0000269|PubMed:11001928,
FT                   ECO:0000269|PubMed:12019207, ECO:0000269|PubMed:14722920,
FT                   ECO:0000269|PubMed:25544560, ECO:0000269|PubMed:9931343"
FT                   /id="VAR_019474"
FT   VARIANT         187
FT                   /note="T -> A (in EPM2; abolishes interaction with NHLRC1)"
FT                   /evidence="ECO:0000269|PubMed:12560877"
FT                   /id="VAR_019475"
FT   VARIANT         194
FT                   /note="T -> I (in EPM2; results in ubiquitin-positive
FT                   perinuclear aggregates; loss of phosphatase activity;
FT                   affects glycogen binding; reduced self-interaction
FT                   capacity; abolishes interaction with NHLRC1, PPP1R3C and
FT                   PRKAA2; no effect on phosphorylation of protein;
FT                   dbSNP:rs375544596)"
FT                   /evidence="ECO:0000269|PubMed:12019207,
FT                   ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:9931343"
FT                   /id="VAR_019476"
FT   VARIANT         210
FT                   /note="E -> K (in EPM2)"
FT                   /evidence="ECO:0000269|PubMed:18311786"
FT                   /id="VAR_046385"
FT   VARIANT         240
FT                   /note="G -> S (in EPM2; impaired phosphatase activity; does
FT                   not affect glycogen binding; disrupts the interaction with
FT                   PPP1R3C)"
FT                   /evidence="ECO:0000269|PubMed:11175283,
FT                   ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:25544560"
FT                   /id="VAR_019477"
FT   VARIANT         279
FT                   /note="G -> S (in EPM2; results in ubiquitin-positive
FT                   perinuclear aggregates; loss of phosphatase activity;
FT                   affects glycogen binding; disrupts the interaction with
FT                   PPP1R3C; dbSNP:rs137852917)"
FT                   /evidence="ECO:0000269|PubMed:12019207,
FT                   ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:14722920,
FT                   ECO:0000269|PubMed:9771710, ECO:0000269|PubMed:9931343"
FT                   /id="VAR_019478"
FT   VARIANT         293
FT                   /note="Q -> L (in EPM2; results in ubiquitin-positive
FT                   perinuclear aggregates; may affect proper folding; loss of
FT                   phosphatase activity; affects glycogen binding; disrupts
FT                   the interaction with PPP1R3C; dbSNP:rs796052427)"
FT                   /evidence="ECO:0000269|PubMed:11001928,
FT                   ECO:0000269|PubMed:12019207, ECO:0000269|PubMed:14532330,
FT                   ECO:0000269|PubMed:9771710"
FT                   /id="VAR_019479"
FT   VARIANT         294
FT                   /note="Y -> N (in EPM2; results in ubiquitin-positive
FT                   perinuclear aggregates; impairs phosphatase activity;
FT                   affects glycogen binding; disrupts the interaction with
FT                   PPP1R3C)"
FT                   /evidence="ECO:0000269|PubMed:12019207,
FT                   ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:25544560,
FT                   ECO:0000269|PubMed:9931343"
FT                   /id="VAR_019480"
FT   VARIANT         301
FT                   /note="P -> L (in EPM2; impairs protein stability; impairs
FT                   phosphatase activity; affects glycogen binding; disrupts
FT                   the interaction with PPP1R3C; dbSNP:rs796052428)"
FT                   /evidence="ECO:0000269|PubMed:11175283,
FT                   ECO:0000269|PubMed:14532330, ECO:0000269|PubMed:25544560"
FT                   /id="VAR_019481"
FT   VARIANT         310
FT                   /note="L -> W (in EPM2; causes location of isoform 1 at
FT                   cytoplasmic punctae; does not affect homodimerization of
FT                   isoform 1 but prevents heterodimerization of isoform 1 and
FT                   isoform 2)"
FT                   /evidence="ECO:0000269|PubMed:18311786"
FT                   /id="VAR_046386"
FT   MUTAGEN         8
FT                   /note="V->A: Loss of phosphatase activity. No effect on
FT                   glycogen binding."
FT                   /evidence="ECO:0000269|PubMed:25544560"
FT   MUTAGEN         25
FT                   /note="S->A: Partial loss of phosphatase activity.
FT                   Abolishes homodimerization. Abolishes interaction with
FT                   NHLRC1, PPP1R3C and PRKAA2. Does not affect glycogen
FT                   binding. Reduces stability of the protein."
FT                   /evidence="ECO:0000269|PubMed:21728993"
FT   MUTAGEN         25
FT                   /note="S->D: Partial loss of phosphatase activity.
FT                   Increases interaction with NHLRC1. Does not affect
FT                   interaction with NHLRC1, PPP1R3C or PRKAA2. Does not affect
FT                   binding to carbohydrate. Does not affect homodimerization."
FT                   /evidence="ECO:0000269|PubMed:21728993"
FT   MUTAGEN         87
FT                   /note="K->A: Loss of phosphatase activity. Abolishes
FT                   glycogen binding."
FT                   /evidence="ECO:0000269|PubMed:11739371,
FT                   ECO:0000269|PubMed:25544560"
FT   MUTAGEN         99
FT                   /note="W->A: Strongly reduces phosphatase activity.
FT                   Strongly reduces glycogen binding."
FT                   /evidence="ECO:0000269|PubMed:25544560"
FT   MUTAGEN         109..110
FT                   /note="CC->SS: No effect on homodimerization or
FT                   carbohydrate binding. Decreased phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:23922729"
FT   MUTAGEN         123
FT                   /note="C->S: No effect on homodimerization or carbohydrate
FT                   binding. Decreased phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:23922729"
FT   MUTAGEN         126
FT                   /note="I->T: Strongly decreased phosphatase activity. No
FT                   effect on glycogen binding."
FT                   /evidence="ECO:0000269|PubMed:25544560"
FT   MUTAGEN         142
FT                   /note="T->A: Strongly decreased phosphatase activity. No
FT                   effect on glycogen binding."
FT                   /evidence="ECO:0000269|PubMed:25544560"
FT   MUTAGEN         168
FT                   /note="S->A,D: Abolishes interaction with NHLRC1."
FT                   /evidence="ECO:0000269|PubMed:21728993"
FT   MUTAGEN         169
FT                   /note="C->S: No effect on homodimerization or carbohydrate
FT                   binding. Decreased phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:23922729"
FT   MUTAGEN         169
FT                   /note="C->S: No effect on phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:25538239"
FT   MUTAGEN         171
FT                   /note="R->A: No effect on phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:25538239"
FT   MUTAGEN         187
FT                   /note="T->D: Abolishes interaction with NHLRC1."
FT                   /evidence="ECO:0000269|PubMed:21728993"
FT   MUTAGEN         194
FT                   /note="T->D: Does not affect interaction with NHLRC1,
FT                   PPP1R3C or PRKAA2."
FT                   /evidence="ECO:0000269|PubMed:21728993"
FT   MUTAGEN         197
FT                   /note="D->A: Strongly decreased phosphatase activity. No
FT                   effect on glycogen binding."
FT                   /evidence="ECO:0000269|PubMed:25538239,
FT                   ECO:0000269|PubMed:25544560"
FT   MUTAGEN         205
FT                   /note="C->S: No effect on homodimerization or carbohydrate
FT                   binding. Decreased phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:23922729"
FT   MUTAGEN         235
FT                   /note="D->A: Complete loss of phosphatase activity. Does
FT                   not affect glycogen binding."
FT                   /evidence="ECO:0000269|PubMed:14532330,
FT                   ECO:0000269|PubMed:25538239"
FT   MUTAGEN         236
FT                   /note="M->A: Complete loss of phosphatase activity. No
FT                   effect on glycogen binding."
FT                   /evidence="ECO:0000269|PubMed:25544560"
FT   MUTAGEN         250
FT                   /note="C->S: No effect on homodimerization or carbohydrate
FT                   binding. Decreased phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:23922729"
FT   MUTAGEN         251
FT                   /note="L->A: Impairs protein stability. Strongly reduces
FT                   phosphatase activity. No effect on glycogen binding."
FT                   /evidence="ECO:0000269|PubMed:25544560"
FT   MUTAGEN         266
FT                   /note="C->S: Complete loss of phosphatase activity. Does
FT                   not affect glycogen binding. Does not affect
FT                   self-interaction. Increases the interaction with PPP1R3C."
FT                   /evidence="ECO:0000269|PubMed:11220751,
FT                   ECO:0000269|PubMed:11739371, ECO:0000269|PubMed:14532330,
FT                   ECO:0000269|PubMed:22036712, ECO:0000269|PubMed:23922729,
FT                   ECO:0000269|PubMed:25538239, ECO:0000269|PubMed:25544560"
FT   MUTAGEN         272
FT                   /note="R->A: Complete loss of phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:25538239"
FT   MUTAGEN         321
FT                   /note="F->S: Impairs protein stability. Strongly reduces
FT                   phosphatase activity. No effect on glycogen binding."
FT                   /evidence="ECO:0000269|PubMed:25544560"
FT   MUTAGEN         329..331
FT                   /note="Missing: Fails to homodimerize. Does not affect
FT                   carbohydrate binding or phosphatase activity."
FT                   /evidence="ECO:0000269|PubMed:23922729"
FT   MUTAGEN         329
FT                   /note="C->S: Fails to homodimerize. Does not affect
FT                   carbohydrate binding, interaction with NHLRC1, phosphatase
FT                   activity, or ubiquitination by NHLRC1."
FT                   /evidence="ECO:0000269|PubMed:23922729"
FT   MUTAGEN         329
FT                   /note="C->S: No effect on homodimerization."
FT                   /evidence="ECO:0000269|PubMed:25538239"
FT   CONFLICT        193
FT                   /note="Q -> K (in Ref. 8; AAH70047)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        248
FT                   /note="A -> P (in Ref. 4; AAO15523)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        258
FT                   /note="K -> E (in Ref. 5; BAG61454)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        294
FT                   /note="Y -> H (in Ref. 5; BAG61454)"
FT                   /evidence="ECO:0000305"
FT   STRAND          1..9
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   HELIX           11..14
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   STRAND          19..26
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   HELIX           27..29
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   TURN            30..32
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   HELIX           34..36
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   STRAND          58..67
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   STRAND          84..91
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   STRAND          97..103
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   HELIX           104..106
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   STRAND          108..110
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   HELIX           114..116
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   STRAND          121..123
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   HELIX           138..151
FT                   /evidence="ECO:0007829|PDB:4RKK"
FT   STRAND          157..161
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   STRAND          164..167
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   HELIX           173..177
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   HELIX           178..183
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   STRAND          188..191
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   HELIX           195..201
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   HELIX           203..205
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   STRAND          208..210
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   HELIX           214..223
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   STRAND          227..230
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   HELIX           238..258
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   STRAND          262..265
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   HELIX           271..283
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   HELIX           289..296
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   STRAND          303..305
FT                   /evidence="ECO:0007829|PDB:4R30"
FT   HELIX           307..321
FT                   /evidence="ECO:0007829|PDB:4R30"
SQ   SEQUENCE   331 AA;  37158 MW;  DD79F917262AB458 CRC64;
     MRFRFGVVVP PAVAGARPEL LVVGSRPELG RWEPRGAVRL RPAGTAAGDG ALALQEPGLW
     LGEVELAAEE AAQDGAEPGR VDTFWYKFLK REPGGELSWE GNGPHHDRCC TYNENNLVDG
     VYCLPIGHWI EATGHTNEMK HTTDFYFNIA GHQAMHYSRI LPNIWLGSCP RQVEHVTIKL
     KHELGITAVM NFQTEWDIVQ NSSGCNRYPE PMTPDTMIKL YREEGLAYIW MPTPDMSTEG
     RVQMLPQAVC LLHALLEKGH IVYVHCNAGV GRSTAAVCGW LQYVMGWNLR KVQYFLMAKR
     PAVYIDEEAL ARAQEDFFQK FGKVRSSVCS L
//
